On June 24, 2026, the U.S. Food and Drug Administration (FDA) approved palbociclib (Ibrance, Pfizer Inc.) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment. This marks a significant expansion of palbociclib’s approved indications and represents the first CDK4/6 inhibitor-based maintenance regimen approved in the HR+/HER2+ metastatic setting.

Clinical Takeaway

✔ Palbociclib added to trastuzumab ± pertuzumab and endocrine therapy significantly improved progression-free survival as maintenance therapy in HR+/HER2+ metastatic breast cancer patients who did not progress on taxane-based induction.

✔ A hazard ratio of 0.76 (95% CI: 0.59–0.97) was observed.

✔ Palbociclib received Breakthrough Therapy Designation for this indication, underscoring the unmet need and clinical significance of this approval.

Drug Profile & Mechanism

  • Drug: Palbociclib (Ibrance), manufactured by Pfizer Inc.
  • Class: Cyclin-dependent kinase (CDK) 4/6 inhibitor
  • Mechanism: Inhibits CDK4 and CDK6, blocking cell cycle progression from G1 to S phase and suppressing tumor cell proliferation in hormone receptor-positive breast cancer
  • New indication: Maintenance treatment in combination with trastuzumab ± pertuzumab and endocrine therapy for adults with HR+/HER2+ locally advanced or metastatic breast cancer following induction treatment
  • Regulatory designation: Breakthrough Therapy Designation granted for this indication

Target Population

  • Indication: Adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer
  • Eligibility criterion: No evidence of disease progression following induction treatment with a taxane and trastuzumab, with or without pertuzumab, for advanced disease
  • Patients must have completed induction chemotherapy prior to initiating this maintenance regimen

Study Design

  • Trial name: PATINA (NCT02947685)
  • Design: Randomized, open-label phase III trial
  • Sample size: 518 patients with HR+/HER2+ locally advanced or metastatic breast cancer
  • Randomization: 1:1 ratio
    • Experimental arm: Palbociclib + trastuzumab ± pertuzumab + endocrine therapy (fulvestrant or an aromatase inhibitor: anastrozole, letrozole, or exemestane)
    • Control arm: Trastuzumab ± pertuzumab + endocrine therapy alone
  • Treatment duration: Until disease progression or unacceptable toxicity
  • Prior therapy requirement: No evidence of progression after induction with a taxane + trastuzumab ± pertuzumab for advanced disease

Endpoints

  • Primary endpoint: Investigator-assessed progression-free survival (PFS) per RECIST v1.1
  • Additional endpoint: Overall survival (OS) — data were not mature at the time of the PFS analysis

Efficacy Outcomes

  • A statistically significant improvement in investigator-assessed PFS was observed in the palbociclib combination arm versus the control arm
    • Hazard ratio (HR): 0.76 (95% CI: 0.59–0.97)
    • One-sided p-value: 0.0134
  • Median PFS could not be adequately described due to censoring in the dataset
  • Overall survival data were immature at the time of the PFS analysis; long-term OS results are pending

Safety

The prescribing information for palbociclib in this new indication includes the following warnings and precautions:

  • Neutropenia
  • Interstitial lung disease (ILD) / Pneumonitis
  • Embryo-fetal toxicity

Recommended Dosage

  • Palbociclib: 125 mg orally once daily for 21 consecutive days, followed by 7 days off treatment, constituting a complete 28-day cycle
  • Dosing for trastuzumab, pertuzumab, and endocrine therapy partners should follow their respective prescribing information

Key Clinical Implications

✔ This approval establishes a new maintenance strategy for HR+/HER2+ metastatic breast cancer, a population that has historically been managed with anti-HER2 therapy and endocrine therapy alone after completing chemotherapy-based induction.

✔ The dual targeting of HER2 and CDK4/6 pathways in combination with endocrine therapy reflects the biologic rationale of addressing both HER2-driven and hormone receptor-driven proliferative signaling simultaneously in this co-positive tumor subtype.

✔ Clinicians should identify eligible patients early — specifically those who have completed taxane + trastuzumab ± pertuzumab induction without progression — to assess suitability for this maintenance regimen prior to transitioning off chemotherapy.

✔ Neutropenia monitoring remains essential; oncology teams should establish baseline CBC protocols and patient education on infectious precautions consistent with CDK4/6 inhibitor use.

✔ OS data remain immature, and continued follow-up from the PATINA trial will be important to establish whether the PFS benefit translates into a survival advantage in this patient population.

✔ Healthcare professionals should report serious adverse events associated with palbociclib or any other medication to the FDA MedWatch Reporting System online or by calling 1-800-FDA-1088.

Bottom Line

The FDA approval of palbociclib in combination with trastuzumab ± pertuzumab and endocrine therapy for maintenance treatment in HR+/HER2+ locally advanced or metastatic breast cancer is supported by a statistically significant PFS benefit from the randomized PATINA trial (HR 0.76; p=0.0134). This regimen represents the first CDK4/6 inhibitor-containing maintenance option approved in this co-positive subgroup and offers oncologists a new evidence-based tool for prolonging disease control in patients who have responded to standard taxane and anti-HER2 induction therapy. Ongoing OS follow-up and real-world safety monitoring will be key to fully characterizing the long-term benefit-risk profile of this regimen.

Sources:

  • U.S. Food and Drug Administration. (2026). FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for maintenance treatment of HR-positive, HER2-positive locally advanced or metastatic breast cancer. FDA Oncology (Drugs@FDA / Resources for Information on Approved Drugs). https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-palbociclib-trastuzumab-or-without-pertuzumab-and-endocrine-therapy-maintenance